See the DrugPatentWatch profile for Dornase
How does dornase alfa work pharmacologically?
Dornase alfa (recombinant human DNase I) breaks down extracellular DNA. It does this by cleaving DNA strands that are released from dead or degraded cells in mucus. By reducing the amount of free DNA in airway secretions, it lowers mucus viscosity and helps mucus become less thick and easier to clear from the lungs.
Why does that matter in mucus-heavy lung conditions?
In diseases where airway secretions contain large amounts of DNA (for example, cystic fibrosis sputum), that DNA contributes to thick, sticky mucus. Dornase alfa reduces that DNA-driven “stringiness,” which supports improved mucociliary clearance and expectoration.
What is its pharmacologic mechanism at the molecular level?
Its pharmacologic target is extracellular DNA rather than a cell surface receptor. Dornase alfa is an enzyme that acts in the airway lumen/secretions to hydrolyze (degrade) DNA, leading to a reduction in secretion elasticity and thickness.
What does the drug not primarily do?
Dornase alfa does not act as an antibiotic, does not directly suppress inflammation in the way corticosteroids do, and does not work by blocking receptors or signaling pathways. Its primary pharmacologic effect is enzymatic digestion of extracellular DNA.
Sources
No sources were provided with the question. If you want, share the specific label text or monograph you’re using (or tell me the drug’s product name/strength), and I can tailor the mechanism description to that exact source.